Heron Therapeutics to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026GlobeNewsWire • Tuesday
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/10/26
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026GlobeNewsWire • 07/27/26
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 05/11/26
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/26
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms GuidanceGlobeNewsWire • 05/11/26
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/04/26
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026GlobeNewsWire • 04/27/26
Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to SayZacks Investment Research • 02/26/26
Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewsWire • 02/26/26
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026GlobeNewsWire • 02/17/26
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 GrowthGlobeNewsWire • 01/09/26
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)GlobeNewsWire • 12/04/25
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/04/25
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/04/25
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial ProgressGlobeNewsWire • 11/04/25